Pre-launch · We're opening Reserve Meds to a limited first cohort. Join the waitlist ›

Veozah in Turkey

How patients in Turkey access Veozah (fezolinetant) via Named Patient Program.

Veozah - overview

Veozah (fezolinetant) is manufactured by Astellas and indicated for moderate-to-severe vasomotor symptoms (hot flashes and night sweats) due to menopause. It is an oral tablet, 45 mg once daily approved by the US FDA in 2023 and may be accessible to patients in Turkey through a Named Patient Program or personal-import pathway.

Access in Turkey

Turkey's TITCK operates a named-patient program; HCPs coordinate with Turkish Pharmacists' Association.

How Reserve Meds coordinates access in Turkey

  1. Patient or treating physician submits a request.
  2. We verify clinical appropriateness and Turkey-specific eligibility.
  3. Treating physician in Turkey issues prescription and clinical justification.
  4. Country-specific NPP/personal-import forms are prepared and filed.
  5. We source Veozah from a DSCSA-compliant US specialty wholesaler.
  6. Cold-chain shipment to the patient's physician or hospital pharmacy in Turkey.

Typical timeline for Turkey

End-to-end, most requests are completed in 2-6 weeks. Turkey's tier 2 regulatory maturity typically supports moderate processing times.

What patients and physicians in Turkey ask

  • Is the pathway legal in Turkey? Yes - it operates under Turkey's established NPP or personal-import framework.
  • Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
  • What physician credentials do I need? A licensed physician in Turkey able to issue the prescription and clinical justification.
  • What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
  • Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.

Start a request for Veozah in Turkey

Join the Veozah waitlist

YELLOW
AI Regulatory Review Agent, preliminary signal
Biologic drug requires TITCK import confirmation for the specific patient indication. Cold-chain shipping validated. Typically 2-4 week approval.
Rule: biologic_moh_confirmation • Reviewed 2026-04-22

Join the waitlist

Review & oversight. Content on this page is reviewed by Reserve Meds's clinical and regulatory team. A US-licensed pharmacist reviews every prescription before dispensing. Regulatory posture is informational, not legal advice; case-specific questions route to retained outside counsel. Review methodology ›
Last medically reviewed: .